Title : Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Pub. Date : 2018 Jan 15

PMID : 28960265






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. cabozantinib fms related receptor tyrosine kinase 3 Homo sapiens
2 BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies. cabozantinib fms related receptor tyrosine kinase 3 Homo sapiens
3 CONCLUSIONS: Cabozantinib is well tolerated in AML patients at an MTD of 40 mg daily and is a potent inhibitor of FLT3/ITD- and F691 TKD-altered tyrosine kinases. cabozantinib fms related receptor tyrosine kinase 3 Homo sapiens